A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Adam Friedman, MD: Hello, and welcome to Medscape Care Cues. I'm Dr Adam Friedman and I'm joined by my good friend and colleague, Dr Shawn Kwatra. Welcome, Shawn. Shawn G. Kwatra, MD: Thanks so ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

100% of patients with a single 240 mg dose had complete response at week 8. Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...